CytomX Therapeutics (CTMX)
(Real Time Quote from BATS)
$1.15 USD
0.00 (0.00%)
Updated Oct 2, 2024 10:46 AM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for CytomX Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 175 | 194 | 305 | 316 | 296 |
Receivables | 3 | 36 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 7 | 4 | 7 | 7 |
Total Current Assets | 183 | 237 | 310 | 324 | 303 |
Net Property & Equipment | 4 | 5 | 6 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 1 | 1 | 2 | 3 | 3 |
Total Assets | 202 | 261 | 339 | 359 | 341 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 5 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 29 | 34 | 23 | 30 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 132 | 121 | 69 | 75 | 51 |
Total Current Liabilities | 156 | 153 | 106 | 101 | 86 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 80 | 180 | 126 | 186 | 179 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 0 | 0 | 0 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 249 | 347 | 250 | 309 | 290 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 676 | 637 | 623 | 500 | 468 |
Retained Earnings | -723 | -723 | -534 | -450 | -417 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -47 | -86 | 89 | 50 | 51 |
Total Liabilities & Shareholder's Equity | 202 | 261 | 339 | 359 | 341 |
Total Common Equity | -47 | -86 | 89 | 50 | 51 |
Shares Outstanding | 66.90 | 66.00 | 65.20 | 48.20 | 45.50 |
Book Value Per Share | -0.71 | -1.30 | 1.37 | 1.03 | 1.12 |
Fiscal Year End for CytomX Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 137 | 150 | 175 | 194 | 181 |
Receivables | 3 | 13 | 3 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 5 | 5 | 5 |
Total Current Assets | 143 | 167 | 183 | 201 | 188 |
Net Property & Equipment | 3 | 4 | 4 | 4 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 2 | 2 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 159 | 185 | 202 | 221 | 209 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 2 | 1 | 2 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 5 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 14 | 18 | 21 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 124 | 124 | 132 | 124 | 120 |
Total Current Liabilities | 143 | 145 | 156 | 147 | 141 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 37 | 60 | 80 | 112 | 141 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4 | 4 | 3 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 190 | 216 | 249 | 272 | 294 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 685 | 678 | 676 | 673 | 642 |
Retained Earnings | -716 | -710 | -723 | -724 | -727 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -31 | -32 | -47 | -51 | -85 |
Total Liabilities & Shareholder's Equity | 159 | 185 | 202 | 221 | 209 |
Total Common Equity | -31 | -32 | -47 | -51 | -85 |
Shares Outstanding | 77.90 | 68.10 | 66.90 | 66.70 | 66.30 |
Book Value Per Share | -0.40 | -0.47 | -0.71 | -0.77 | -1.28 |